Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Natalya Iorio, Zubair Malik & Ron Schey. (2015) Profile of rifaximin and its potential in the treatment of irritable bowel syndrome. Clinical and Experimental Gastroenterology 8, pages 159-167.
Read now
Read now
Lucrezia Laterza, Gianluca Ianiro, Iolanda Scoleri, Rosario Landi, Giovanni Bruno, Franco Scaldaferri, Eleonora Gaetani, Mariachiara Campanale & Antonio Gasbarrini. (2015) Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy 16:4, pages 607-615.
Read now
Read now
Articles from other publishers (8)
Babita Veer & Ram Singh. (2019) Facile synthesis of 2-arylimidazo[1,2-a]pyridines catalysed by DBU in aqueous ethanol. Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences 475:2230, pages 20190238.
Crossref
Crossref
Mark S Riddle, Patrick Connor, Jamie Fraser, Chad K Porter, Brett Swierczewski, Emma J Hutley, Brook Danboise, Mark P Simons, Christine Hulseberg, Tahaniyat Lalani, Ramiro L Gutierrez, David R Tribble, Matthew Adam, Ernest Akorli, Rachael Armstrong, Lucy Ashford-Brown, Jaime Alvarado, Ricardo Aviles, Charlotte Ayres, Timothy Ballard, Liam Barry, Mary Bavaro, Catherine Berjohn, Robert Bjoraker, Peter Blenkinsop, Jason Blitz, Jeromy Boucher, Timothy Burgess, Daniel Burns, Jenna Burns, Shauna Butler, Anthony Cancio, Anthony Cardile, Tarah Carnes, Fongkuei Cheng, Katherine Clay, David Cook, Robert Deiss, Charles Duffield, Christopher Duplessis, Rhonda Dyer, Aaron Farmer, Robert Gormley, Antonia Hazlerigg, Jewell Hemmings, Neil Hill, Emily Hollis, Jack Hutter, Alshia Johnson, Paul Kartchner, Fred KencyJr.Jr., Kelly Latimer, Julian Lentaigne, Andrew Letizia, Jason Maguire, Jennifer Masel, Ryan Maves, Aline Miura, Lynette Moore, Olamide Oladipo, Shane Patterson, Mark Pence, Adrian Proffitt, Joanna Rimmer, Benjamin Rodriguez, Carlo Rossi, Claire Royston, Melanie Sanders, Karen Santiago, Thomas Scorer, Amanda Self, Akira Shishido, Mildred Sitonik, Daniel Snyder, Garrick Stride, Hamilton Tilley, Matthew Timlin, Melanie Trado, Detonya Tulsie, Lavanya Viswanathan, Tyler Warkentien, J T A Wedgwood & Samuel White. (2017) Trial Evaluating Ambulatory Therapy of Travelers’ Diarrhea (TrEAT TD) Study: A Randomized Controlled Trial Comparing 3 Single-Dose Antibiotic Regimens With Loperamide. Clinical Infectious Diseases 65:12, pages 2008-2017.
Crossref
Crossref
Avital Beig, Noa Fine-Shamir, David Lindley, Jonathan M Miller & Arik Dahan. (2017) Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability. The AAPS Journal 19:3, pages 806-813.
Crossref
Crossref
Farah Babakhani, Jaime Seddon & Pamela Sears. (2014) Comparative Microbiological Studies of Transcription Inhibitors Fidaxomicin and the Rifamycins in Clostridium difficile. Antimicrobial Agents and Chemotherapy 58:5, pages 2934-2937.
Crossref
Crossref
John R. Peters. 2014. FDA Bioequivalence Standards. FDA Bioequivalence Standards
243
274
.
Sarah S Lewis & Deverick J Anderson. (2013)
Treatment of
Clostridium difficile
infection: recent trial results
. Clinical Investigation 3:9, pages 875-886.
Crossref
Crossref
Mike Starr. (2013) Paediatric travel medicine: vaccines and medications. British Journal of Clinical Pharmacology 75:6, pages 1422-1432.
Crossref
Crossref
K. W. Garey, S. S. Ghantoji, D. N. Shah, M. Habib, V. Arora, Z.-D. Jiang & H. L. DuPont. (2011) A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. Journal of Antimicrobial Chemotherapy 66:12, pages 2850-2855.
Crossref
Crossref